ASCO-SITC Clinical Immuno-Oncology Symposim

Please visit Board H8 for the following abstract:

 

Abstract 124: Development and correlative analysis of a TML assay in specimens with reference MSI and somatic variant results.

 

Thursday, February 28: 11:30 AM-1:00 PM and 6:00 PM-7:00 PM
San Francisco Marriott Marquis | San Francisco, CA

 

First Author: Hestia Mellert, Ph.D. Director of Development, Biodesix

Dr. Hestia Mellert is the Director of the Development group at Biodesix, Inc. With a doctorate in cancer biology, she leads teams in the development and commercialization of blood-based diagnostic tests approved by CAP, CLIA, ISO 13485 and NYS CLEP. Dr. Mellert has played a leading role in the enhancement of GeneStrat, including the launch of EML4-ALK, ROS1 and RET fusion tests. She continues to focus her efforts on bringing relevant and actionable information to physicians in the academic and community setting. Dr. Mellert received her Ph.D from the University of Pennsylvania and post-doctoral training at the University of Colorado where she was an American Cancer Society Post-doctoral Fellow.

 

 

Interested in Biodesix?

Contact us